A Phase II Prospective, Randomized, Double‐Blind, Placebo‐Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor‐Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting

LESSONS LEARNED: The levels of circulating follicle‐stimulating hormone, luteinizing hormone, estriol, estradiol, and estrone remained unchanged after a 12‐week treatment with 0.005% estriol vaginal gel in postmenopausal women receiving nonsteroidal aromatase inhibitors for hormone receptor‐positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez‐Rovira, Pedro, Hirschberg, Angelica Lindén, Gil‐Gil, Miguel, Bermejo‐De Las Heras, Begoña, Nieto‐Magro, Concepción
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108054/
https://www.ncbi.nlm.nih.gov/pubmed/32459035
http://dx.doi.org/10.1634/theoncologist.2020-0417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108054/
https://www.ncbi.nlm.nih.gov/pubmed/32459035
http://dx.doi.org/10.1634/theoncologist.2020-0417

Ejemplares similares